Atlas Trials

Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

Clinical trial NCT07686263 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07686263
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Status
NOT_YET_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Schizophrenia
Start date
2026-09-03
Primary completion
2029-03-03
Enrollment
472

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.